IL-11 was isolated in 1990 (Paul et al., 1990), and recombinant human IL-11 (rhIL-11) was developed and marketed to reduce chemotherapy-induced thrombocytopenia but its clinical use is limited by the requirement of multiple daily injections and severe adverse effects in humans (Hauer-Jensen, 2014). This evidence concerns the gene IL11 and Thrombocytopenia.